Cancer and Pregnancy: Parallels in Growth, Invasion, and Immune Modulation and Implications for Cancer Therapeutic Agents

Holtan, Shernan G.; Creedon, Douglas J.; Haluska, Paul; Markovic, Svetomir N.
November 2009
Mayo Clinic Proceedings;Nov2009, Vol. 84 Issue 11, p985
Academic Journal
Many proliferative, invasive, and Immune tolerance mechanisms that support normal human pregnancy are also exploited by malignancies to establish a nutrient supply and evade or edit the host immune response. In addition to the shared capacity for invading through normal tissues, both cancer cells and cells of the developing placenta create a microenvironment supportive of both immunologic privilege and angiogenesis. Systemic alterations in Immunity are also detectable, particularly with respect to a helper T cell type 2 polarization evident In advanced cancers and midtrimester pregnancy. This review summarizes the similarities between growth and immune privilege in cancer and pregnancy and identifies areas for further investigation. Our PubMed search strategy included combinations of terms such as Immune tolerance, pregnancy, cancer, cytokines, angiogenesis, and Invasion. We did not place any restrictions on publication dates. The knowledge gained from analyzing similarities and differences between the physiologic state of pregnancy and the pathologic state of cancer could lead to identification of new potential targets for cancer therapeutic agents.


Related Articles

  • The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Lorena Benedetti; Maria Romina Girotti; Federico Prada; Edgardo Salvatierra; Andrea Llera // Cancer & Metastasis Reviews;Sep2008, Vol. 27 Issue 3, p523 

    Abstract  Tumor growth is essentially the result of an evolving cross-talk between malignant and surrounding stromal cells (fibroblasts, endothelial cells and inflammatory cells). This heterogeneous mass of extracellular matrix and intermingled cells interact through cell–cell and...

  • Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harbouring KRAS, BRAF and PIK3CA Mutations. Brandi, Giovanni; Tavolari, Simona; Rosa, Francesco De; Di Girolamo, Stefania; Agostini, Valentina; Barbera, Maria Aurelia; Frega, Giorgio; Biasco, Guido // PLoS ONE;Jul2012, Vol. 7 Issue 7, p1 

    The employment of anti-epidermal growth factor receptor (EGFR) antibodies represents a backbone of the therapeutic options for the treatment of metastatic colorectal cancer (mCRC). However, this therapy is poorly effective or ineffective in unselected patients. Mutations in KRAS, BRAF and PIK3CA...

  • Advances in a(v)�(3) Integrin-Targeting Cancer Therapy and Imaging with Radiolabeled RGD Peptides. Mitrasinovic, Petar M. // Current Radiopharmaceuticals;Jul2009, Vol. 2 Issue 3, p214 

    There is a family of proteins - integrins, which are generally expressed at low levels on epithelial cells and mature endothelial cells, but they are highly expressed on the surface of both endothelial cells in tumor neovasculature and some tumor cells, including osteosarcomas, neuroblastomas,...

  • Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy. Wright, Paul K. // Recent Patents on Anti-Cancer Drug Discovery;Jun2008, Vol. 3 Issue 2, p137 

    Cancer is a common disease in Western society that can affect any organ system. It has a high morbidity and mortality despite advances in treatment over the last hundred years. There is a clear need for new approaches to cancer chemotherapy including the possibility of reducing systemic adverse...

  • "Buy One Get One Free": Armed Viruses for the Treatment of Cancer Cells and their Microenvironment. Kaur, Balveen; Cripe, Timothy P.; Chiocca, E. Antonio // Current Gene Therapy;Oct2009, Vol. 9 Issue 5, p341 

    Oncolytic viral therapy is a promising biological therapy for the treatment of cancer. Recent advances in genetic engineering have facilitated the construction of custom-built oncolytic viruses that can be exquisitely targeted to tumors by exploiting each cancer's unique biology and their...

  • The STATs of cancer — new molecular targets come of age. Hua Yu; Jove, Richard // Nature Reviews Cancer;Feb2004, Vol. 4 Issue 2, p97 

    Tumour cells acquire the ability to proliferate uncontrollably, resist apoptosis, sustain angiogenesis and evade immune surveillance. STAT proteins — especially STAT3 and STAT5 — regulate all of these processes and are persistently activated in a surprisingly large number of human...

  • Glioma Stem Cell Maintenance: The Role of the Microenvironment. Heddleston, John M.; Hitomi, Masahiro; Venere, Monica; Flavahan, William A.; Yang, Kenneth; Kim, Youngmi; Minhas, Sana; Rich, Jeremy N.; Hjelmeland, Anita B. // Current Pharmaceutical Design;8/1/2011, Vol. 17 Issue 23, p2386 

    Glioblastomas are highly lethal cancers for which conventional therapies provide only palliation. The cellular heterogeneity of glioblastomas is manifest in genetic and epigenetic variation with both stochastic and hierarchical models informing cellular phenotypes. At the apex of the hierarchy...

  • Vascular remodeling in cancer. Farnsworth, R H; Lackmann, M; Achen, M G; Stacker, S A // Oncogene;7/3/2014, Vol. 33 Issue 27, p3496 

    The growth and dissemination of tumors rely on an altered vascular network, which supports their survival and expansion and provides accessibility to the vasculature and a route of transport for metastasizing tumor cells. The remodeling of vascular structures through generation of new vessels...

  • Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide–paclitaxel conjugate in mice with breast cancer. Cao, Qizhen; Li, Zi-Bo; Chen, Kai; Wu, Zhanhong; He, Lina; Neamati, Nouri; Chen, Xiaoyuan // European Journal of Nuclear Medicine & Molecular Imaging;Aug2008, Vol. 35 Issue 8, p1489 

    Targeting drugs to receptors involved in tumor angiogenesis has been demonstrated as a novel and promising approach to improve cancer treatment. In this study, we evaluated the anti-tumor efficacy of a dimeric RGD peptide–paclitaxel conjugate (RGD2–PTX) in an orthotopic MDA-MB-435...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics